サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1712717

インターロイキン阻害剤の世界市場レポート 2025年

Interleukin Inhibitors Global Market Report 2025

出版日
ページ情報
英文 250 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.94円
インターロイキン阻害剤の世界市場レポート 2025年
出版日: 2025年04月09日
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インターロイキン阻害剤市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR18.0％で966億6,000万米ドルに成長します。予測期間の成長は、新たな治療適応症、世界の高齢化、免疫療法の併用、研究開発投資の増加に起因すると考えられます。予測期間における主な動向としては、経口インターロイキン阻害剤、次世代治療、小児適応、アクセス拡大、患者中心の医療などが挙げられます。

乾癬、関節炎、炎症性腸疾患などの炎症性疾患に対する治験薬の開発が急ピッチで進んでおり、インターロイキン阻害剤市場を牽引しています。これらの阻害剤は炎症性サイトカインの作用を抑制し、組織の平衡を保ち、宿主の免疫反応への害を防ぐ。現在、炎症性疾患の治療薬として48の分子が検討されており、うち20分子は第III相臨床試験段階にあります。承認されれば、この強力なパイプラインがインターロイキン阻害剤市場を牽引すると予想されます。

細菌感染症の罹患率の増加は、インターロイキン阻害剤市場の今後の成長を促進すると予想されます。微細な単細胞生物によって引き起こされる細菌感染症は、健康に重大な課題をもたらします。インターロイキン阻害剤は、細菌の増殖を抑制することで、細菌性疾患の治療と予防に重要な役割を果たしています。例えば、2024年3月、米国を拠点とする政府機関である疾病対策予防センター（Centers for Disease Control and Prevention）は、結核患者が2022年の8,320人から2023年には9,615人に急増し、1,295人増加したと報告しました。したがって、細菌感染症の有病率の上昇がインターロイキン阻害剤市場の拡大に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界インターロイキン阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のインターロイキン阻害剤市場：成長率分析
  • 世界のインターロイキン阻害剤市場の実績：規模と成長, 2019-2024
  • 世界のインターロイキン阻害剤市場の予測：規模と成長, 2024-2029, 2034F
  • 世界インターロイキン阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のインターロイキン阻害剤市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • IL-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • その他のタイプ
  • 世界のインターロイキン阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 乾癬
  • 乾癬性関節炎
  • 関節リウマチ
  • 喘息
  • 炎症性腸疾患（IBD）
  • その他の用途
  • 世界のインターロイキン阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のインターロイキン阻害剤市場IL-17のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • セクキヌマブ
  • イキセキズマブ
  • ブロダルマブ
  • 世界のインターロイキン阻害剤市場IL-23のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ウステキヌマブ
  • グセルクマブ
  • チルドラキズマブ
  • 世界のインターロイキン阻害剤市場IL-1のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • アナキンラ
  • カナキヌマブ
  • 世界のインターロイキン阻害剤市場IL-5のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • メポリズマブ
  • レスリズマブ
  • ベンラリズマブ
  • 世界のインターロイキン阻害剤市場IL-6のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • トシリズマブ
  • サリルマブ
  • 世界のインターロイキン阻害剤市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • その他のインターロイキン阻害剤

第7章 地域別・国別分析

  • 世界のインターロイキン阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界のインターロイキン阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • インターロイキン阻害剤市場：競合情勢
  • インターロイキン阻害剤市場：企業プロファイル
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Eli Lilly and Company
  • AstraZeneca plc
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Limited
  • Boehringer Ingelheim International GmbH
  • Janssen Biotech Inc.
  • Ortho Dermatologics
  • Amgen Inc.
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck & Co. Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • インターロイキン阻害剤市場2029：新たな機会を提供する国
  • インターロイキン阻害剤市場2029：新たな機会を提供するセグメント
  • インターロイキン阻害剤市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r32928

Interleukin inhibitors are substances utilized to dampen the immune system's activity by impeding the function of interleukins. Interleukins belong to a group of cytokines produced by white blood cells (lymphocytes, monocytes, and macrophages) in response to infections, playing a vital role in immune system regulation.

The primary types of interleukin inhibitors encompass IL-17, IL-23, IL-1, IL-5, IL-6, among others. Interleukin 17, a pro-inflammatory cytokine from the cystine knot family, is produced by a specific subset of T helper cells called T helper 17 cells upon stimulation by IL-23. These inhibitors find application in treating conditions like psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and more. They are distributed through various channels, including hospital pharmacies, retail outlets, and online pharmacies.

The interleukin inhibitors market research report is one of a series of new reports from The Business Research Company that provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with an interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.'

The interleukin inhibitors market size has grown rapidly in recent years. It will grow from $42.93 billion in 2024 to $49.84 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to rising prevalence of autoimmune diseases, increasing awareness of interleukin inhibitors, growing demand for personalized medicine, growing elderly population, and growing popularity of biosimilars.

The interleukin inhibitors market size is expected to see rapid growth in the next few years. It will grow to $96.66 billion in 2029 at a compound annual growth rate (CAGR) of 18.0%. The growth in the forecast period can be attributed to emerging therapeutic indications, the global aging population, immunotherapy combinations, and increasing investment in research and development. Major trends in the forecast period include oral interleukin inhibitors, next-generation therapies, pediatric indications, expanded access, and patient-centric care.

The burgeoning development of investigational drugs for inflammatory diseases like psoriasis, arthritis, and inflammatory bowel disease is set to propel the interleukin inhibitors market. These inhibitors curtail the actions of inflammatory cytokines, preserving tissue equilibrium and preventing harm to the host's immune responses. Presently, 48 molecules are under scrutiny for treating inflammatory conditions, with 20 in Phase III clinical trials. Upon approval, this robust pipeline is expected to drive the interleukin inhibitors market.

The increasing incidence of bacterial infections is anticipated to propel the growth of the interleukin inhibitors market in the coming years. Bacterial infections, caused by microscopic single-celled organisms, pose significant health challenges. Interleukin inhibitors play a crucial role in treating and preventing bacterial diseases by inhibiting bacterial growth. For example, in March 2024, the Centers for Disease Control and Prevention, a U.S.-based government agency, reported that tuberculosis cases surged from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. Therefore, the rising prevalence of bacterial infections is significantly contributing to the expansion of the interleukin inhibitors market.

The expiration of patents for biologic drugs creates pathways for biosimilars, presenting a more cost-effective alternative. Major players in the interleukin sector concentrate on biosimilar development for inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), pursued by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions. Despite the clinical advantages, limited patient access to biological therapy, primarily due to elevated treatment costs, drives the biosimilars trend. Rapid advancements in biotechnology and analytical sciences ensure biosimilar comparability to biological drugs, further bolstering this trend.

Leading market players are securing regulatory nods for novel antibiotic formulations. For instance, Risankizumab-rzaa, an FDA-approved interleukin-23 (IL-23) inhibitor, gained approval in June 2022 for treating adults with moderately to severely active Crohn's disease (CD). These drugs target specific cytokines and immune pathways, mitigating inflammation and enhancing patient outcomes, showcasing the market's commitment to innovative pharmaceuticals.

Major companies operating in the interleukin inhibitors market include Sanofi S.A., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., AbbVie Inc., Sun Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Janssen Biotech Inc., Ortho Dermatologics, Amgen Inc., Celgene Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Seattle Genetics Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Astellas Pharma Inc., Ipsen Biopharmaceuticals Inc.

North America was the largest region in the interleukin inhibitors market in 2024. The regions covered in the interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Interleukin Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on interleukin inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for interleukin inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The interleukin inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: IL-17; IL-23; IL-1; IL-5; IL-6; Other Types
  • 2) By Application: Psoriasis; Psoriatic Arthritis; Rheumatoid Arthritis; Asthma; Inflammatory Bowel Disease; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By IL-17: Secukinumab; Ixekizumab; Brodalumab
  • 2) By IL-23: Ustekinumab; Guselkumab; Tildrakizumab
  • 3) By IL-1: Anakinra; Canakinumab
  • 4) By IL-5: Mepolizumab; Reslizumab; Benralizumab
  • 5) By IL-6: Tocilizumab; Sarilumab
  • 6) By Other Types: Other Interleukin Inhibitors
  • Companies Mentioned: Sanofi S.A.; GlaxoSmithKline plc; Novartis International AG; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Interleukin Inhibitors Market Characteristics

3. Interleukin Inhibitors Market Trends And Strategies

4. Interleukin Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Interleukin Inhibitors Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Interleukin Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Interleukin Inhibitors Market Growth Rate Analysis
  • 5.4. Global Interleukin Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Interleukin Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Interleukin Inhibitors Total Addressable Market (TAM)

6. Interleukin Inhibitors Market Segmentation

  • 6.1. Global Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • IL-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Other Types
  • 6.2. Global Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease (IBD)
  • Other Applications
  • 6.3. Global Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Interleukin Inhibitors Market, Sub-Segmentation Of IL-17, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Secukinumab
  • Ixekizumab
  • Brodalumab
  • 6.5. Global Interleukin Inhibitors Market, Sub-Segmentation Of IL-23, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ustekinumab
  • Guselkumab
  • Tildrakizumab
  • 6.6. Global Interleukin Inhibitors Market, Sub-Segmentation Of IL-1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Anakinra
  • Canakinumab
  • 6.7. Global Interleukin Inhibitors Market, Sub-Segmentation Of IL-5, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • 6.8. Global Interleukin Inhibitors Market, Sub-Segmentation Of IL-6, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tocilizumab
  • Sarilumab
  • 6.9. Global Interleukin Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Other Interleukin Inhibitors

7. Interleukin Inhibitors Market Regional And Country Analysis

  • 7.1. Global Interleukin Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Interleukin Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Interleukin Inhibitors Market

  • 8.1. Asia-Pacific Interleukin Inhibitors Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Interleukin Inhibitors Market

  • 9.1. China Interleukin Inhibitors Market Overview
  • 9.2. China Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Interleukin Inhibitors Market

  • 10.1. India Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Interleukin Inhibitors Market

  • 11.1. Japan Interleukin Inhibitors Market Overview
  • 11.2. Japan Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Interleukin Inhibitors Market

  • 12.1. Australia Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Interleukin Inhibitors Market

  • 13.1. Indonesia Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Interleukin Inhibitors Market

  • 14.1. South Korea Interleukin Inhibitors Market Overview
  • 14.2. South Korea Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Interleukin Inhibitors Market

  • 15.1. Western Europe Interleukin Inhibitors Market Overview
  • 15.2. Western Europe Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Interleukin Inhibitors Market

  • 16.1. UK Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Interleukin Inhibitors Market

  • 17.1. Germany Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Interleukin Inhibitors Market

  • 18.1. France Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Interleukin Inhibitors Market

  • 19.1. Italy Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Interleukin Inhibitors Market

  • 20.1. Spain Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Interleukin Inhibitors Market

  • 21.1. Eastern Europe Interleukin Inhibitors Market Overview
  • 21.2. Eastern Europe Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Interleukin Inhibitors Market

  • 22.1. Russia Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Interleukin Inhibitors Market

  • 23.1. North America Interleukin Inhibitors Market Overview
  • 23.2. North America Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Interleukin Inhibitors Market

  • 24.1. USA Interleukin Inhibitors Market Overview
  • 24.2. USA Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Interleukin Inhibitors Market

  • 25.1. Canada Interleukin Inhibitors Market Overview
  • 25.2. Canada Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Interleukin Inhibitors Market

  • 26.1. South America Interleukin Inhibitors Market Overview
  • 26.2. South America Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Interleukin Inhibitors Market

  • 27.1. Brazil Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Interleukin Inhibitors Market

  • 28.1. Middle East Interleukin Inhibitors Market Overview
  • 28.2. Middle East Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Interleukin Inhibitors Market

  • 29.1. Africa Interleukin Inhibitors Market Overview
  • 29.2. Africa Interleukin Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Interleukin Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Interleukin Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Interleukin Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Interleukin Inhibitors Market Competitive Landscape
  • 30.2. Interleukin Inhibitors Market Company Profiles
    • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Interleukin Inhibitors Market Other Major And Innovative Companies

  • 31.1. Eli Lilly and Company
  • 31.2. AstraZeneca plc
  • 31.3. Teva Pharmaceutical Industries Ltd.
  • 31.4. Regeneron Pharmaceuticals Inc.
  • 31.5. Bausch Health Companies Inc.
  • 31.6. AbbVie Inc.
  • 31.7. Sun Pharmaceutical Industries Limited
  • 31.8. Boehringer Ingelheim International GmbH
  • 31.9. Janssen Biotech Inc.
  • 31.10. Ortho Dermatologics
  • 31.11. Amgen Inc.
  • 31.12. Celgene Corporation
  • 31.13. Bristol-Myers Squibb Company
  • 31.14. Pfizer Inc.
  • 31.15. Merck & Co. Inc.

32. Global Interleukin Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Interleukin Inhibitors Market

34. Recent Developments In The Interleukin Inhibitors Market

35. Interleukin Inhibitors Market High Potential Countries, Segments and Strategies

  • 35.1 Interleukin Inhibitors Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Interleukin Inhibitors Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Interleukin Inhibitors Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer